CMMB FY 2022 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$57,773

Operating Income

-$29M

Net Income

-$28M

EPS (Diluted)

$-9.68

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$43M

Total Liabilities

$7M

Stockholders' Equity

$36M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$57,773	-$34,023	-69.8%
Operating Income	-$29M	-$12M	-130.7%
Net Income	-$28M	-$12M	-121.6%